2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-101764R
    Lintitript (Standard) 136381-85-6
    Lintitript (Standard) (SR 27897 (Standard)) is the analytical standard of Lintitript (HY-101764). This product is intended for research and analytical applications. Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC50 of 6 nM and a Ki of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC50 value of 200 nM). Lintitript increases plasma concentration of leptin and food intake as well as plasma concentration of insulin.
    Lintitript (Standard)
  • HY-101782R
    HSK0935 (Standard) 1638851-44-1
    HSK0935 (Standard) is the analytical standard of HSK0935 (HY-101782). This product is intended for research and analytical applications. HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC50 of 1.3 nM. Antihyperglycemic activities.
    HSK0935 (Standard)
  • HY-101812R
    Terbufibrol (Standard) 56488-59-6 98%
    Terbufibrol (Standard) is the analytical standard of Terbufibrol (HY-101812). This product is intended for research and analytical applications. Terbufibrol has been shown highly active in reducing serum total cholesterol (TC) levels in the normal and hypercholesterolemic male rat.
    Terbufibrol (Standard)
  • HY-101832R
    SBC-110736 (Standard) 1629166-02-4 98%
    SBC-110736 (Standard) is the analytical standard of SBC-110736 (HY-101832). This product is intended for research and analytical applications. SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor extracted from patent WO2014150395A1.
    SBC-110736 (Standard)
  • HY-101847R
    DBHDA (Standard) 99584-96-0 98%
    DBHDA (Standard) is the analytical standard of DBHDA (HY-101847). This product is intended for research and analytical applications. DBHDA is organic compound, which converts cysteine to dehydroalanine (DHA).
    DBHDA (Standard)
  • HY-101857R
    TP-020 (Standard) 1800025-30-2 98%
    TP-020 (Standard) (MGAT2-IN-1 (Standard)) is the analytical standard of TP-020 (HY-101857). This product is intended for research and analytical applications. TP-020 (MGAT2-IN-1), a chemical probe, is an orally active inhibitor of monoacylglycerol acyltransferase (MGAT2) with IC50 of 7.8 and 2.4 nM for human and mouse MGAT2, respectively.
    TP-020 (Standard)
  • HY-101903R
    BMS-309403 (Standard) 300657-03-8 98%
    BMS-309403 (Standard) is the analytical standard of BMS-309403. This product is intended for research and analytical applications. BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells.
    BMS-309403 (Standard)
  • HY-101906R
    DC260126 (Standard) 346692-04-4 98%
    DC260126 (Standard) is the analytical standard of DC260126 (HY-101906). This product is intended for research and analytical applications. DC260126 is a potent antagonist of GPR40 (FFAR1). DC260126 dose-dependently inhibits GPR40-mediated Ca2+ elevations stimulated by linoleic acid, oleic acid, palmitoleic acid and lauric acid (IC50: 6.28, 5.96, 7.07, 4.58 μM, respectively). DC260126 could protect MIN6 β cells from palmitate-induced ER stress and apoptosis.
    DC260126 (Standard)
  • HY-10195BR
    Ruboxistaurin hydrochloride (Standard) 169939-93-9 98%
    Ruboxistaurin hydrochloride (Standard) is the analytical standard of Ruboxistaurin hydrochloride (HY-10195B). This product is intended for research and analytical applications. Ruboxistaurin (LY333531) hydrochloride is an orally active, selective PKC beta inhibitor (Ki=2 nM). Ruboxistaurin hydrochloride exhibits ATP dependent competitive inhibition of PKC beta I with an IC50 of 4.7 nM. Ruboxistaurin hydrochloride inhibits PKC beta II with an IC50 of 5.9 nM.
    Ruboxistaurin hydrochloride (Standard)
  • HY-101966R
    NCT-503 (Standard) 1916571-90-8 98%
    NCT-503 (Standard) is the analytical standard of NCT-503 (HY-101966). This product is intended for research and analytical applications. NCT-503 is a blood-brain barrier-permeable, non-competitive PHGDH inhibitor with an IC50 of 2.5 μM against human PHGDH. NCT-503 reduces glucose-derived serine production and the incorporation of one-carbon units into nucleotides without decreasing PHGDH protein expression. NCT-503 prevents high selenium-induced insulin resistance in mice by regulating blood glucose and insulin levels and improving glucose tolerance, and also inhibits the growth of tumors overexpressing PHGDH. NCT-503 can be used in research related to insulin resistance and breast cancer.
    NCT-503 (Standard)
  • HY-101972R
    AZ-PFKFB3-67 (Standard) 1704741-11-6
    AZ-PFKFB3-67 (Standard) is the analytical standard of AZ-PFKFB3-67 (HY-101972). This product is intended for research and analytical applications. AZ-PFKFB3-67 is a potent and selective PFKFB3 kinase inhibitor with IC50s of 11, 159 and 1130 nM for PFKFB3, PFKFB2 and PFKFB1, respectively. AZ-PFKFB3-67 reduces MCL-1. AZ-PFKFB3-67 has neuroprotective activity.
    AZ-PFKFB3-67 (Standard)
  • HY-101986R
    BIIE-0246 (Standard) 246146-55-4 98%
    BIIE-0246 (Standard) is the analytical standard of BIIE-0246 (HY-101986). This product is intended for research and analytical applications. BIIE-0246 (AR-H 053591) is a potent and selective NPY2R (neuropeptide Y receptor 2) antagonist with an IC50 value of 15 nM for rat [125I]PYY3-36. BIIE-0246 decreases the expression of p-AKT S473, P-p44/42 MAPK under the NPY-stimulated. BIIE-0246 reduces albuminuria in ADR nephropathy.
    BIIE-0246 (Standard)
  • HY-101998R
    CTP inhibitor (Standard) 412940-35-3 98%
    CTP inhibitor (Standard) is the analytical standard of CTP inhibitor (HY-101998). This product is intended for research and analytical applications. CTP inhibitor (Compound 792949) is a potent and selective CTP inhibitor. CTP inhibitor inhibits the plasma membrane citrate transporter (PMCT).
    CTP inhibitor (Standard)
  • HY-102037R
    SSTR5 antagonist 1 (Standard) 1628741-91-2 98%
    SSTR5 antagonist 1 (Standard) is the analytical standard of SSTR5 antagonist 1 (HY-102037). This product is intended for research and analytical applications. SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC50s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively.
    SSTR5 antagonist 1 (Standard)
  • HY-102045R
    T-3764518 (Standard) 1809151-56-1 98%
    T-3764518 (Standard) is the analytical standard of T-3764518 (HY-102045). This product is intended for research and analytical applications. T-3764518 is a novel and potent stearoyl coenzyme A desaturase (SCD) inhibitor with an IC50 of 4.7 nM.
    T-3764518 (Standard)
  • HY-102052R
    DCEBIO (Standard) 60563-36-2 98%
    DCEBIO (Standard) is the analytical standard of DCEBIO (HY-102052). This product is intended for research and analytical applications. DCEBIO is a small/medium conductance calcium-activated potassium (SKCa/IKCa) channel opener and primary neuron signal blocker. It hyperpolarizes the membrane potential of C2C12 myoblasts by activating IKCa channels, thereby promoting myogenic differentiation. The specific biological activity of DCEBIO is manifested in increased myotube formation, enhanced myosin heavy chain II protein levels and myogenin mRNA levels. DCEBIO can be applied in the field of muscle research, especially in muscle-related degenerative diseases such as sarcopenia.
    DCEBIO (Standard)
  • HY-102056R
    BAY 59-9435 (Standard) 654059-21-9 98%
    BAY 59-9435 (Standard) is the analytical standard of BAY 59-9435 (HY-102056). This product is intended for research and analytical applications. BAY 59-9435 is a potent and selective inhibitor of Hormone Sensitive Lipase (HSL), with an IC50 of 0.023 μM.
    BAY 59-9435 (Standard)
  • HY-102065R
    SC-19220 (Standard) 19395-87-0 98%
    SC-19220 (Standard) is the analytical standard of SC-19220 (HY-102065). This product is intended for research and analytical applications. SC-19220 is a prostaglandin E2 receptor EP1 antagonist. SC-19220 blocks functional EP1 receptor activation, and RANK/RANKL signaling pathway. SC-19220 inhibits osteoclast formation and bone resorption by pre-existing osteoclasts. SC-19220 can be used for the research of osteoporotic disorders, inflammatory bone resorption.
    SC-19220 (Standard)
  • HY-102079R
    SAFit1 (Standard) 1643125-32-9 98%
    SAFit1 (Standard) is the analytical standard of SAFit1 (HY-102079). This product is intended for research and analytical applications. SAFit1 is a FK506 binding protein 51 (FKBP51)-specific inhibitor with a Ki of 4±0.3 nM.
    SAFit1 (Standard)
  • HY-10284S4
    Linagliptin-d5 98%
    Linagliptin-d5 (BI 1356-d5) is deuterium labeled Linagliptin. Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.
    Linagliptin-d5
Cat. No. Product Name / Synonyms Application Reactivity